CytRx Corporation (CYTR)
| Market Cap | 87.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.28M |
| Shares Out | 35.20M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.40 |
| Previous Close | $2.42 |
| Change ($) | -0.02 |
| Change (%) | -0.83% |
| Day's Open | 2.57 |
| Day's Range | 2.31 - 2.60 |
| Day's Volume | 355,176 |
| 52-Week Range | 0.35 - 2.75 |
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurod...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today h...
About CYTR
CytRx Corporation, a biopharmaceutical company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstre... [Read more...]
| Industry Biotechnology | IPO Date Nov 10, 1986 |
| CEO Steven Kriegsman | Employees 4 |
| Stock Exchange OTCMKTS | Ticker Symbol CYTR |
Analyst Forecasts
The average 12-month stock price forecast for CYTR is 4.50, which is an increase of 87.50% from the latest price.